FDA Approves Bluebird’s $2.8 Million Gene Therapy for Rare Blood Disease

FDA Approves Bluebird’s $2.8 Million Gene Therapy for Rare Blood Disease
·5 min read

The FDA approved a first-of-its-kind treatment from Bluebird Bio that represents a potential cure for a rare blood disorder at a price of $2.8 million per patient.